Jackson Creek Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Jackson Creek Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.66M	Hold	8,313	–	–	0.49%	91
2025 Q4	$1.57M	Sell	8,313 -6,157	-43%	-$1.18M	0.46%	100
2025 Q3	$2.56M	Sell	14,470 -6	-0%	-$892	0.74%	6
2025 Q2	$1.65M	Buy	14,476 +2,051	+17%	+$219K	0.44%	109
2025 Q1	$1.31M	Sell	12,425 -4,522	-27%	-$511K	0.42%	129
2024 Q4	$1.82M	Sell	16,947 -529	-3%	-$59.8K	0.55%	31
2024 Q3	$1.75M	Buy	17,476 +3,876	+29%	+$390K	0.52%	45
2024 Q2	$1.15M	Sell	13,600 -24	-0.2%	-$1.91K	0.42%	81
2024 Q1	$996K	Sell	13,624 -29	-0.2%	-$2.14K	0.36%	158
2023 Q4	$975K	Sell	13,653 -4	-0%	-$236	0.37%	136
2023 Q3	$818K	Sell	13,657 -10	-0.1%	-$658	0.35%	155
2023 Q2	$985K	Buy	13,667 +941	+7%	+$70.6K	0.39%	92
2023 Q1	$936K	Buy	+12,726	New	+$905K	0.39%	84
2022 Q4	–	Sell	-15,429	Closed	-$829K	–	340
2022 Q3	$829K	Buy	+15,429	New	+$907K	0.39%	116
2020 Q4	–	Sell	-11,671	Closed	-$694K	–	332
2020 Q3	$694K	Buy	+11,671	New	+$796K	0.31%	175

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Jackson Creek Investment Advisors's LGND Position: Q1 2026 in Review

Jackson Creek Investment Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 8,313 shares worth $1.66M. The position accounts for 0.49% of the portfolio, ranked #91.

Jackson Creek Investment Advisors first reported a position in LGND in Q3 2020 and has held it in 15 quarters since. The position peaked at $2.56M in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Jackson Creek Investment Advisors held 8,313 shares of Ligand Pharmaceuticals worth $1.66M as of Q1 2026.
Jackson Creek Investment Advisors left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
Ligand Pharmaceuticals made up 0.49% of Jackson Creek Investment Advisors's portfolio in Q1 2026, its #91 holding.
Jackson Creek Investment Advisors first reported a position in Ligand Pharmaceuticals in Q3 2020 and has held it in 15 quarters since.
Jackson Creek Investment Advisors's Ligand Pharmaceuticals position peaked at $2.56M in Q3 2025.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2026, filed 5 May 2026.